Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0300891620933672 http://scihub22266oqcxt.onion/10.1177/0300891620933672 32508257!ä!32508257 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Tumori 2020 ; 106 (4): 271-272 Nephropedia Template TP {{tp|p=32508257|t=2020. Patients with cancer in the COVID-19 era: the clinical trial issue |pdf=|usr=}}{{32508257}} gab.com Text Patients with cancer in the COVID-19 era: the clinical trial issue JO: Tumori http://www.kidney.de/pget.php?&tw=1&pmid=32508257 #FOAvip Coronavirus disease 2019 (COVID-19) hospital reorganization may result in reduced ability for the hospital to fully use its armamentarium for battling cancer. Thus different therapeutic modalities have been recommended. During the pandemic, despite regulatory agencies' recommendations, several considerations and doubts remain for oncologic clinical trials. Considering patients who had been enrolled before the pandemic, and who plan to take the study medication, the situation becomes complicated. These patients should undergo monitoring visits, blood sampling, questionnaire, physical examination, and drug and radiation administration. To avoid deviations from the protocol and trial discontinuation, follow-up should be performed regularly, in concordance with safety guidelines. Here we report several considerations. Twit Text FOAVip Patients with cancer in the COVID-19 era: the clinical trial issue ????Tumori http://www.kidney.de/pget.php?&tw=1&pmid=32508257 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32508257 #FOAvip English Wikipedia <ref>{{Cite pmid|32508257}}</ref> Patients with cancer in the COVID-19 era: the clinical trial issue #MMPMID32508257 Scarcia M; Ludovico GM; Fortunato A; Fiorentino A Tumori 2020[Aug]; 106 (4): 271-272 PMID32508257show ga Coronavirus disease 2019 (COVID-19) hospital reorganization may result in reduced ability for the hospital to fully use its armamentarium for battling cancer. Thus different therapeutic modalities have been recommended. During the pandemic, despite regulatory agencies' recommendations, several considerations and doubts remain for oncologic clinical trials. Considering patients who had been enrolled before the pandemic, and who plan to take the study medication, the situation becomes complicated. These patients should undergo monitoring visits, blood sampling, questionnaire, physical examination, and drug and radiation administration. To avoid deviations from the protocol and trial discontinuation, follow-up should be performed regularly, in concordance with safety guidelines. Here we report several considerations. |Betacoronavirus/*pathogenicity[MESH] |COVID-19[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/complications/*therapy/virology[MESH] |Humans[MESH] |Medical Oncology/*trends[MESH] |Neoplasms/complications/*therapy/virology[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/*therapy/virology[MESH] |SARS-CoV-2[MESH]Patients with cancer in the COVID-19 era: the clinical trial issue (epmc).pdf DeepDyve Pubget Overpricing